今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

聚合顺(605166.SH)2023年度每股派0.285元 慷慨分红彰显发展信心

上海，2024年6月14日 - 聚合顺(605166.SH)今日发布公告，宣布公司2023年度每股派息0.285元人民币（含税），共计派息金额约为2.34亿元人民币。

本次利润分配方案经公司2024年6月13日召开的第九届董事会第三十一次会议审议通过。

股权登记日为2024年6月20日，凡在股权登记日当日持有本公司股份的股东均有权享受本次利润分配。

除权后，公司将于2024年6月21日起恢复除息交易。

**聚合顺是一家专业从事聚丙烯（PP）改性材料研发、生产和销售的高新技术企业。**公司产品广泛应用于汽车、家电、电子、纺织等领域。

**2023年，受下游需求疲软影响，聚合顺盈利能力有所下降。**尽管如此，公司仍坚持现金分红的股东回报政策，以体现对股东的尊重和回报。

本次利润分配体现了公司对股东的长期承诺，有利于增强股东信心，促进公司持续健康发展。

聚合顺(605166.SH)2023年度利润分配方案亮点:

• **每股派息0.285元，彰显股东回报力度。**尽管公司2023年盈利能力有所下降，但仍坚持现金分红，体现了公司对股东的长期承诺和负责任的态度。
• **派息金额2.34亿元，体现公司财务稳健。**公司派息金额占公司可分配利润的比例较高，体现了公司财务状况稳健、现金流充裕。
• **股权登记日为6月20日，投资者可提前做好安排。**公司提前公布股权登记日，方便投资者提前做好资金安排，参与本次利润分配。

总体而言，聚合顺(605166.SH)2023年度利润分配方案充分体现了公司对股东的尊重和回报，有利于增强投资者信心，促进公司持续健康发展。

以下是一些关于聚合顺(605166.SH)的额外信息：

• 聚合顺(605166.SH)是国家重点支持的高新技术企业，入选国家创新型企业名录。
• 公司积极布局新能源领域，已成为国内领先的PP改性材料供应商之一。
• 公司未来将继续坚持科技创新，推动公司高质量发展。

请注意：

• 本文仅供参考，不构成任何投资建议。
• 本文中的信息可能存在误差或遗漏，恕不承担任何责任。